[123I]β‐CIT single‐photon emission tomography in DOPA‐responsive dystonia

Naumann, Markus; Pirker, Walter; Reiners, Karlheinz; Lange, Klaus W.; Becker, Georg; Brücke, Thomas

doi:10.1002/mds.870120330

Cited by 43 publications

(19 citation statements)

References 17 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DAT may directly reflect the function of nigrostriatal dopaminergic terminals [15][16][17][18]. Our findings were very similar to the studies by Naumann et al [19] and Jeon et al [20], who also reported a normal function in another DAT binding with [ 123 I]-β-CIT study. The diagnosis of DRD was based on the positive family history, childhood onset of dystonia, progressive A B C Fig.…”

Section: Discussionsupporting

confidence: 94%

“…Besides, to our knowledge, there have been only a few reports of the use of 123 I-β-CIT to investigate the role of DAT in DRD [19][20][21][22]. For further understanding of the mechanism of DAT in DRD patients, we performed DAT with 99m Tc-TRODAT-1 study in two patients with DRD who came from the same family.The results of 99m Tc-TRODAT-1 are reported and possible mechanisms are discussed.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Normal dopamine transporter binding in dopa responsive dystonia

Huang¹,

Yen

Weng³

et al. 2002

Journal of Neurology

View full text Add to dashboard Cite

We report the clinical manifestations of dopa responsive dystonia (DRD) in 2 patients from the same family. The brain magnetic resonance images (MRI) were normal. The dopamine transporter (DAT) imaging with (99m)Tc-TRODAT-1 was performed in the 2 probands, 8 patients with young onset Parkinson disease (YOPD) and 16 normal controls. The ratios of (99m)Tc-TRODAT-1 brain SPECT in the striatum were 2.40 +/- 0.12 (right) and 2.30 +/- 0.17 (left) in these 2 DRD patients as compared with 1.38 +/- 0.18 (right), 1.41 +/- 0.20 (left) in YOPD patients, and 2.15 +/- 0.35 (right), 2.14 +/- 0.32 (left) in normal controls respectively. A normal DAT uptake was found in DRD suggesting a normal presynaptic nigrostriatal dopaminergic terminal. We conclude that a normal DAT in parkinsonian patients can differentiate DRD from YOPD. In addition, DAT with (99m)Tc-TRODAT-1 is a reliable and convenient tool to study the function of the presynaptic dopaminergic axonal terminals.

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Introductionmentioning

confidence: 98%

Normal dopamine transporter binding in dopa responsive dystonia

Huang¹,

Yen

Weng³

et al. 2002

Journal of Neurology

View full text Add to dashboard Cite

show abstract

“…Clinically, DRD presents with a dystonic gait disorder, with slowness of movements, instability, and occasionally tremor, which in some stages may resemble PD. The disease responds well to dopaminergic medication and, in contrast to juvenile parkinsonism, presents with normal striatal DAT binding (64,65). Therefore, for example, if the patient history is unclear, 123 I-FP-CIT SPECT examinations may help to differentiate between DRD and juvenile parkinsonism.…”

Section: Dopa-responsive Dystonia (Drd)mentioning

confidence: 99%

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

2013

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the radiopharmaceuticals used to evaluate nigrostriatal dopamine imaging; (2) the pattern of uptake of these radiopharmaceuticals in parkinsonian syndromes; and (3) the role of these radiopharmaceuticals in the evaluation of parkinsonian syndromes.Financial Disclosure: Dr. Tatsch is a meeting participant/lecturer for GE Healthcare. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, participants can access this activity through the SNMMI Web site (http:// www.snmmi.org/ce_online) through August 2016.This article gives an update on nigrostriatal dopamine terminal imaging, with emphasis on SPECT performed with the presynaptic dopamine transporter (DAT) ligand 123 I-FP-CIT. The paper covers the rational use of this technique in the diagnostic work-up of patients with known or suspected parkinsonian syndromes. In detail, it addresses the impact of the method for the proof or exclusion of neurodegenerative parkinsonism, for its early and preclinical diagnosis, and for the evaluation of disease progression. The importance of normal DAT binding for differentiating symptomatic parkinsonism and relevant tremor syndromes from neurodegeneration is highlighted. Particularly emphasized is the role of DAT SPECT for diagnosing Lewy body dementia and its separation from Alzheimer dementia. Finally, some remarks deal with the economic aspects of the use of these imaging techniques in the clinical setting.

show abstract

“…Our findings and previous reports have all shown that DRD can be clearly differentiated from EOIP by using an [ 18 F]dopa PET [7, 8, 9]or DAT SPECT scan [3, 4, 5, 6]. Striatal binding of [ 18 F]dopa by using PET is normal or only mildly reduced, and that of DAT ligands labeled with [ 123 I] or [ 99m Tc] by using SPECT are normal in DRD but reduced in EOIP; however, the expense and limited availability of PET preclude its widespread clinical application.…”

Section: Discussionmentioning

confidence: 80%

“…Both dopamine transporter (DAT) single-photon emission computed tomography (SPECT) using [ 123 I]-based or [ 99m Tc]-based ligands and [ 18 F]dopa positron emission tomography (PET) have shown normal or only mildly reduced striatal uptake in DRD and clearly differentiate DRD from EOIP [3, 4, 5, 6, 7, 8, 9]. Dopamine D2 receptor densities are reported to be normal or elevated in DRD patients [10, 11], while [ 123 I]IBZM SPECT or [ 11 C]raclopride PET have shown initial upregulation of striatal dopamine D2 receptors in the contralateral putamen of early-stage idiopathic parkinsonism [12, 13], and normal [12]or reduced [14, 15, 16]D2 receptor densities in fluctuating idiopathic parkinsonism.…”

Section: Introductionmentioning

confidence: 99%

Clinical and [99mTc]TRODAT-1/[123I]IBZM SPECT Imaging Findings in Dopa-Responsive Dystonia

Hwang

Yao²,

Wey³

et al. 2004

Eur Neurol

View full text Add to dashboard Cite

We report the clinical and dopamine transporter/D2 receptor single-photon emission computed tomographic (SPECT) imaging findings in a 39-year-old woman with a 24-year history of dopa-responsive dystonia (DRD). The SPECT imaging of the dopamine transporter with [^99mTc]TRODAT-1 is helpful in differentiating DRD from early-onset idiopathic parkinsonism. In the later clinical course, the [¹²³I]IBZM SPECT is also helpful in differentiating these two conditions. The patient showed a dramatic and sustained response to levodopa, and needed a smaller dose of levodopa for symptom control in the later course.

show abstract

[¹²³I]β‐CIT single‐photon emission tomography in DOPA‐responsive dystonia

Cited by 43 publications

References 17 publications

Normal dopamine transporter binding in dopa responsive dystonia

Normal dopamine transporter binding in dopa responsive dystonia

Nigrostriatal Dopamine Terminal Imaging with Dopamine Transporter SPECT: An Update

Clinical and [<sup>99m</sup>Tc]TRODAT-1/[<sup>123</sup>I]IBZM SPECT Imaging Findings in Dopa-Responsive Dystonia

Contact Info

Product

Resources

About